The superfamily of G-protein coupled receptors (GPCRs) is one of the largest gene families in the mammalian genome. GPCRs represent 450% of all current drug targets for treating numerous diseases that affect both peripheral and central nervous systems. Identification of novel GPCR drug targets and their promise for treatment in psychiatric disease has been recently slowed by the dearth of selective targets and changes in the pharmaceutical landscape. However, several recent advances in GPCR crystallization and in vivo pharmacology offer potentially exciting opportunities for therapeutics that target GPCRs in unique ways to treat psychiatric diseases (Kenakin and Christopoulos, 2013) .
Current mathematical and pharmacological data support the conclusion that GPCRs are pluridimensional proteins that occupy numerous structural conformations and signaling states. Depending on the ligand, the GPCR has the ability to engage a G-protein and arrestin state, or favor one over the other (Figure 1 ). These conformations are determined by the type of ligand, the receptor type, as well as interacting accessory proteins. This concept termed 'functional selectivity' (also called, biased signaling, ligand-directed signaling) is the ability of a ligand to direct a GPCR toward a conformation that selectively evokes a particular stimulus-response and is now a wellaccepted concept in the field of GPCR research. Some GPCR classes that have been studied in the context of functional selectivity in vitro and in vivo include: serotonin, opioid, adrenergic, cannabinoid, muscarinic, and metabotropic glutamate receptors (Luttrell and Gesty-Palmer, 2010) .
A recent and elegant development in this field has the potential to greatly advance our understanding of functional selectivity and to open new doors for drug discovery. The study uncovered a 'snapshot' of the serotonin 5HT 2B receptor bound to ergotamine, an arrestin-biased ligand at this receptor (Wacker et al, 2013) . For the first time, this paper and its complementary study, elucidated the molecular signature of the G-protein vs arrestin-biased conformation at serotonin receptors using an X-ray crystallography approach. Together, these reports suggest that for a GPCR to occupy an arrestin-biased (alternateagonist) state, the ligand-receptor conformation sits in an intermediate state that includes both active and inactivate components, yet also interferes with G-protein signaling.
While the authors show convincing modeling for other GPCR types, whether this is indeed case for other biased ligands of other classes of GPCRs remains to be explored. However, this exciting result has the potential to accelerate our understanding of GPCR structure-function relationships, particularly as new ligands are developed for the treatment of psychiatric diseases. Having a clearer understanding of how various ligand types interact with and stabilize GPCR conformations will provide chemists with the necessary tools to rationally design more selective compounds with better delivery, higher affinity, and fewer unwanted side effects.
Complimentary to these exciting molecular advances, contemporary reports have shown promising in vivo data indicating that functionally selective ligands may offer novel strategies to achieve pain relief without the traditional abuse liability, dysphorigenic properties, or psychomimetic components of traditional opioid receptor ligands (Bruchas and Chavkin, 2010; Bruchas et al, 2011) by selectively targeting G-protein vs arrestinbiased signaling states. Furthermore, advances in dopamine and serotonin receptor behavioral pharmacology have revealed that engaging D2R arrestin-biased signaling to GSK3b or 5HT 2A arrestin-biased Src/Akt signaling may offer selective treatments for schizophrenia, psychosis, and other mood disorders (Schmid and Bohn, Similarly, ligands can be antagonists for both pathways, or only one pathway while agonizing the other (collateral agonists). This structurebased signaling complexity is thought to give rise to multiple different downstream outputs, and may involve additional, currently uncharacterized effectors. As we increase our understanding of the molecular architecture of these signaling states, the development of novel psychiatric treatments that target these states will become increasingly more possible. RtlKE3hOWy59KK/story.html). Although the reasons why rates have risen are not entirely known and remain debated, the individual and societal costs necessitate an improved understanding. In this context, examining food and eating behaviors from interdisciplinary perspectives seems important in addressing an obesity epidemic. Historically, obesity has been viewed from a metabolic perspective, with a focus on energy balance (Ziauddeen et al, 2012) . More recently, it has been questioned whether obesity might be conceptualized within an addiction framework and whether certain foods may be addictive (Gearhardt et al, 2011a) . Over time, a motivating factor for food consumption has shifted from sustenance and energy balance to pleasurable/hedonic purposes. Thus, motivational factors (positive-reinforcement-related anticipatory pleasure or negative-reinforcement-related stress reduction) might link to obesity similarly as in drug addictions. Additionally, metabolic factors implicated in homeostatic regulation may relate differently to these constructs in obese as compared with lean individuals.
To examine directly, we studied 25 obese and 25 matched lean individuals using a guided-imagery fMRI task that included individualized cues relating to personal stressors, favorite foods, or neutral-relaxing situations (Jastreboff et al, 2013) . Obese as compared with lean individuals showed increased activation in cortico-striatolimbic structures (striatum, insula, inferior frontal gyrus and amygdala) to favorite-food cues, and activations of thalamus and striatum correlated with subjective craving in obese but not lean individuals. Similarly, stress-related 
